MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of investments
$225,047K
Proceeds from issuance of
common stock upon...
$4,525K
Net cash provided by
(used in) investing...
$134,646K
Net cash provided by
financing activities
$4,525K
Effects of exchange rate
changes on cash, cash...
$2,748K
Canceled cashflow
$90,401K
Net increase
(decrease) in cash, cash...
$65,709K
Canceled cashflow
$76,210K
Purchases of investments
$89,991K
Purchase of property and
equipment
$384K
Purchase of other assets
$26K
Accrued clinical trial
costs
$15,157K
Stock-based compensation
$12,516K
Accrued personnel
expenses
$12,478K
Unrecognized tax benefits
-$2,070K
Prepaid expenses and
other current assets
-$833K
Depreciation and
amortization
$664K
Other accrued
expenses
$469K
Grants receivable
$415K
Unrealized foreign
exchange loss
-$415K
Refundable income taxes
$91K
Net cash used in
operating activities
-$76,210K
Canceled cashflow
$45,108K
Net loss
-$113,341K
Net accretion of
available-for-sale debt securities
-$4,447K
Accounts payable
-$2,900K
Research and development
tax credits...
$493K
Deferred income
-$125K
Change in operating
lease right-of-use...
-$12K
Back
Back
Cash Flow
source: myfinsight.com
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)